Vertex/CRISPR's Sickle Disease Candidate Put On Hold By FDA
Zacks Investment Research | May 30, 2018 10:09PM ET
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and partner CRISPR Therapeutics AG (NASDAQ:CRSP) announced that the FDA has placed a clinical hold on the companies’ investigational new drug (IND) application for CTX001. The companies had filed the IND application last month to start a phase I/II study on CTX00 in sickle cell disease in the United States.
As part of the review of the IND, the FDA will put forward certain questions to the companies. Vertex and CRISPR Therapeutics plan to work rapidly with the FDA to resolve the issue so that the clinical hold is lifted and the study initiated.
In December, as part of a strategic research collaboration formed in 2015, Vertex and CRISPR Therapeutics selected CTX001 to move into clinical development as a gene edited treatment for sickle cell disease and β-thalassemia developed using CRISPR Therapeutics’ proprietary CRISPR/Cas9 technology. Back then, the companies had opted toco-develop and co-commercialize CTX001 and equally share all R&D costs and profits worldwide. Vertex has rights to license up to six new gene editing treatments (including CTX001) developed using the CRISPR/Cas9 technology that emerge from the joint research deal.
An application has also been submitted to begin a phase I/II study in β-thalassemia in 2018 in Europe. The plan to begin this study — in the second half of this year — is intact and unaffected by the hold on the sickle cell disease study.
Shares of CRISPR Therapeutics were down more than 14% in after-hours trading on Wednesday in response to the negative pipeline update while Vertex’s stock did not show any movement. In fact, so far this year CRISPR Therapeutics’ shares have gained 213.4% while that of Vertex are up 4.5% compared to the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.